General Nieuws Regulated Oxurion Announces Extraordinary and Annual Shareholders’ Meetings EN NL april 1, 2022
General Nieuws Regulated Oxurion succesfully raises EUR >10 MILLION from leading US and European healthcare investors in a private equity placement EN NL maart 3, 2022
General Nieuws Regulated Oxurion NV announces 2021 Full Year Results and 2022 Outlook EN NL februari 22, 2022
General Nieuws Oxurion Announces New Data on THR-149 Phase 2 Clinical Trial (“KALAHARI”) in DME at the Angiogenesis, Exudation, and Degeneration 2022 Conference EN februari 14, 2022
General Nieuws Oxurion Announces Upcoming Presentation on THR-149 Phase 2 Clinical Trial (“KALAHARI”) at the Angiogenesis, Exudation, and Degeneration 2022 Conference EN februari 11, 2022
General Nieuws Oxurion to Participate in the 2022 BIO CEO and Investor Conference EN februari 8, 2022
General Nieuws OXURION to Participate in the 10th edition of Degroof Petercam’s Healthcare Conference EN januari 18, 2022
General Nieuws OXURION to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference EN januari 4, 2022
General Nieuws Regulated OXURION NV Secures EUR 10 Million Convertible Bond Financing from Kreos Capital and Pontifax Ventures EN november 22, 2021
General Nieuws First Patient Dosed in Part B of Phase 2 KALAHARI Study Evaluating Multiple Administrations of THR-149 versus aflibercept for Treatment of Diabetic Macular Edema (DME) EN november 15, 2021
General Nieuws Oxurion NV Announces Initiation of Equity Analyst Coverage by H.C. Wainwright with a “Buy” Recommendation EN november 4, 2021
General Nieuws Oxurion NV Announces First Patient Dosed in its Phase 2 Study Evaluating THR-687 for the treatment of Diabetic Macular Edema (DME) EN oktober 13, 2021
General Nieuws Positive Phase 2 Part A THR-149 data shared at the America Society of Retina Specialists (ASRS) Annual Scientific Meeting EN oktober 11, 2021
General Nieuws OXURION to Present at the Lytham Partners Fall 2021 Investor Conference EN oktober 5, 2021
General Nieuws Regulated OXURION Announces Positive Results from Part A of Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME) EN september 30, 2021
